JPRN-UMIN000014888已完成1 期
Everolimus for the treatment of lymphangiomatosis, Gorham-Stout disease and vascular anomalies - Everolimus for vascular anomalies
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 30years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Allergy of everolimus
研究者
相似试验
已完成
1 期
Sirolimus for the treatment of lymphangiomatosis, Gorham-Stout disease and vascular anomaliesymphangiomatosis, Gorham-Stout disease and vascular anomaliesJPRN-UMIN000016580Gifu university30
已完成
不适用
Sirolimus for the treatment of refractory lymphangiomatosis/ Gorham Stout diseaseJPRN-UMIN000029843Kyushu University Hospital2
进行中（未招募）
不适用
Everolimus in der Therapie von Patienten mit pulmonaler Hypertonie-steady or progressive pulmonary hypertension accompanied by at least two of the following parameters associated with a poor prognosis:-Cardiac index = 2,1 l/min/m2-6 MWD = 380 m-systolic RR = 120 mmHg-VO2max = 11 l/min/kg-SVO2 = 60%-Hf = 90/min-probabilty of survival for one year = 0,7 following the NIH-formularMedDRA version: 8.1Level: PTClassification code 10037400Term: Pulmonary hypertensionEUCTR2006-004224-37-DEniversität Leipzig10
进行中（未招募）
1 期
Everolimus (RAD001) in combination with intravenous carboplatin in taxane- and anthracycline-pretreated patients with progressive metastatic breast cancer - RAD001 and carboplatin in pretreated metastatic breast cancerEUCTR2008-006055-52-DECharité - University Hospital of Berlin58
终止
2 期
Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on EverolimusSporadic Angiomyolipomas (AMLs)NCT02539459Fox Chase Cancer Center20